Effect of Acarbose and Vildagliptin on Visceral Fat Distribution in Newly Diagnosed Type 2 Diabetes Patients
Status:
Unknown status
Trial end date:
2018-01-01
Target enrollment:
Participant gender:
Summary
Focusing on newly diagnosed type 2 diabetes participants with overweight and obesity (24kg/m2
≤ body mass index ≤ 30kg/m2).
50 participants per arm (acarbose & lifestyle combination / vildagliptin & lifestyle
combination), using abdominal computed tomography scans and other methods to evaluate the
effects of acarbose and vildagliptin on visceral fat distribution in overweight and obesity
patients with newly diagnosed type 2 diabetes.